{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["chemoradiotherapy", "gastric cancer", "network meta-analysis", "overall survival", "progression-free survival"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "30210338", "DateRevised": {"Year": "2020", "Month": "09", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "08", "Day": "22"}], "Language": ["eng"], "ELocationID": ["929", "10.3389/fphar.2018.00929"], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "9", "PubDate": {"Year": "2018"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Survival Benefit of Three Different Therapies in Postoperative Patients With Advanced Gastric Cancer: A Network Meta-Analysis.", "Pagination": {"StartPage": "929", "MedlinePgn": "929"}, "Abstract": {"AbstractText": ["<b>Purpose:</b> Gastric cancer is mainly treated by gastrectomy, the results of which were unsatisfactory without any adjuvant treatments. This study aimed to examine the performance of radiotherapy, chemotherapy, and chemoradiotherapy after surgery in order to acquire the optimal adjuvant treatment. <b>Method:</b> Embase and PubMed were retrieved to conduct a systematic research. Hazard ratios (HR) of overall survival (OS) and progression-free survival (PFS) as outcomes were calculated by synthesizing direct and indirect evidence to evaluate the efficacy of three treatments against surgery alone. The <i>P</i>-score ranking was utilized to rank the therapies. Consistency was assessed by heat plot. Begg's test was performed to evaluate publication bias. <b>Results:</b> A total of 35 randomized controlled studies (RCTs) with 8973 patients were included in our network meta-analysis (NMA). As for efficacy outcomes, OS and PFS of 1, 2, 3, and 5 years, all revealed chemoradiotherapy (CRT) as the best of three adjuvant therapies. Meanwhile, <i>P</i>-score ranking results also displayed that CRT was the optimal regimen. Additionally, radiotherapy (RT) and chemotherapy (CT) were two alternative options following CRT since RT performed well in short-term survival while CT could improve the long-term survival. <b>Conclusion:</b> CRT was the most recommended therapy to accompany surgery according to our results. However, no analysis about the safety of these three treatments was mentioned in our study. Further studies including safety outcomes were required to draw a more comprehensive conclusion."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Wu", "ForeName": "Dong-Mei", "Initials": "DM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Wang", "ForeName": "Shan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Wen", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Han", "ForeName": "Xin-Rui", "Initials": "XR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Wang", "ForeName": "Yong-Jian", "Initials": "YJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Shen", "ForeName": "Min", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Fan", "ForeName": "Shao-Hua", "Initials": "SH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Zhang", "ForeName": "Zi-Feng", "Initials": "ZF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Zhuang", "ForeName": "Juan", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Shan", "ForeName": "Qun", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Li", "ForeName": "Meng-Qiu", "Initials": "MQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Hu", "ForeName": "Bin", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Sun", "ForeName": "Chun-Hui", "Initials": "CH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Lu", "ForeName": "Jun", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, China."}, {"Identifier": [], "Affiliation": "College of Health Sciences, Jiangsu Normal University, Xuzhou, China."}], "LastName": "Zheng", "ForeName": "Yuan-Lin", "Initials": "YL"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Abe M., Takahashi M., Ono K., Tobe T., Inamoto T. (1988). Japan gastric trials in intraoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 15, 1431\u20131433. 10.1016/0360-3016(88)90239-8", "ArticleIdList": ["10.1016/0360-3016(88)90239-8", "3198440"]}, {"Citation": "Badiani B., Maratea D., Messori A. (2015). Second-line treatments for advanced gastric cancer: interpreting outcomes by network meta-analysis. World J. Clin. Oncol. 6, 73\u201379. 10.5306/wjco.v6.i4.73", "ArticleIdList": ["10.5306/wjco.v6.i4.73", "PMC4530381", "26266104"]}, {"Citation": "Bajetta E., Buzzoni R., Mariani L., Beretta E., Bozzetti F., Bordogna G., et al. . (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the italian trials in medical oncology (ITMO) group. Ann. Oncol. 13, 299\u2013307. 10.1093/annonc/mdf040", "ArticleIdList": ["10.1093/annonc/mdf040", "11886009"]}, {"Citation": "Bamias A., Karina M., Papakostas P., Kostopoulos I., Bobos M., Vourli G., et al. (2010). A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother. Pharmacol. 65, 1009\u20131021. 10.1007/s00280-010-1256-6", "ArticleIdList": ["10.1007/s00280-010-1256-6", "20130877"]}, {"Citation": "Bonfanti G. (1988). Adjuvant treatments following curative resection for gastric cancer. Br. J. Surg. 75, 1100\u20131104. 10.1002/bjs.1800751117", "ArticleIdList": ["10.1002/bjs.1800751117", "2905188"]}, {"Citation": "Bouch\u00e9 O., Ychou M., Burtin P., Bedenne L., Ducreux M., Lebreton G., et al. . (2005). Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann. Oncol. 16, 1488\u20131497. 10.1093/annonc/mdi270", "ArticleIdList": ["10.1093/annonc/mdi270", "15939717"]}, {"Citation": "Brierley J. D. (2017). TNM Classification of Malignant Tumours. Hoboken, NJ: John Wiley & Sons."}, {"Citation": "Calvo F. A., Aristu J. J., Azinovic I., Abuchaibe O., Escude L., Martinez R., et al. . (1992). Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 24, 729\u2013736. 10.1016/0360-3016(92)90721-S", "ArticleIdList": ["10.1016/0360-3016(92)90721-S", "1429097"]}, {"Citation": "Cirera L., Balil A., Batiste-Alentorn E., Tusquets I., Cardona T., Arcusa A., et al. . (1999). Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J. Clin. Oncol. 17, 3810\u20133815. 10.1200/JCO.1999.17.12.3810", "ArticleIdList": ["10.1200/JCO.1999.17.12.3810", "10577853"]}, {"Citation": "Coombes R. C., Schein P. S., Chilvers C. E. D., Wils J., Beretta G., Bliss J. M., et al. . (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol. 8, 1362\u20131369. 10.1200/JCO.1990.8.8.1362", "ArticleIdList": ["10.1200/JCO.1990.8.8.1362", "2199622"]}, {"Citation": "Dai Q., Jiang L., Lin R. J., Wei K. K., Gan L. L., Deng C. H., et al. . (2015). Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J. Surg. Oncol. 111, 277\u2013284. 10.1002/jso.23795", "ArticleIdList": ["10.1002/jso.23795", "25273525"]}, {"Citation": "De Vita F., Giuliani F., Orditura M., Maiello E., Galizia G., Di Martino N., et al. . (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann. Oncol. 18, 1354\u20131358. 10.1093/annonc/mdm128", "ArticleIdList": ["10.1093/annonc/mdm128", "17525087"]}, {"Citation": "Desiderio J., Chao J., Melstrom L., Warner S., Tozzi F., Fong Y., et al. . (2017). The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur. J. Cancer 79, 1\u201314. 10.1016/j.ejca.2017.03.030", "ArticleIdList": ["10.1016/j.ejca.2017.03.030", "PMC5568419", "28456089"]}, {"Citation": "Di Costanzo F., Gasperoni S., Manzione L., Bisagni G., Labianca R., Bravi S., et al. . (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J. Natl. Cancer Inst. 100, 388\u2013398. 10.1093/jnci/djn054", "ArticleIdList": ["10.1093/jnci/djn054", "18334706"]}, {"Citation": "Douglass H. O., Jr., Stablein D. M. (1982). Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49, 1116\u20131122.", "ArticleIdList": ["7037156"]}, {"Citation": "Duo-Ji M. M., Ci-Ren B. S., Long Z. W., Zhang X. H., Luo D. L. (2017). Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis. Oncotarget 8, 37896\u201337911. 10.18632/oncotarget.14664", "ArticleIdList": ["10.18632/oncotarget.14664", "PMC5514960", "28099947"]}, {"Citation": "Engstrom P. F., Lavin P. T., Douglass H. O., Jr., Brunner K. W. (1985). Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. eastern cooperative oncology group study (EST 3275). Cancer 55, 1868\u20131873.", "ArticleIdList": ["3884131"]}, {"Citation": "Grau J. J., Estap\u00e9 J., Alcobendas F., Pera C., Daniels M., Teres J. (1993). Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur. J. Cancer 29A, 340\u2013342. 10.1016/0959-8049(93)90381-O", "ArticleIdList": ["10.1016/0959-8049(93)90381-O", "8398330"]}, {"Citation": "Hallissey M. T., Dunn J. A., Ward L. C., Allum W. H. (1994). The second british stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343, 1309\u20131312. 10.1016/S0140-6736(94)92464-3", "ArticleIdList": ["10.1016/S0140-6736(94)92464-3", "7910321"]}, {"Citation": "Hermans J., Bonenkamp J. J., Boon M. C., Bunt A. M., Ohyama S., Sasako M., et al. . (1993). Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11, 1441\u20131447. 10.1200/JCO.1993.11.8.1441", "ArticleIdList": ["10.1200/JCO.1993.11.8.1441", "8336183"]}, {"Citation": "Hu B., El Hajj N., Sittler S., Lammert N., Barnes R., Meloni-Ehrig A. (2012). Gastric cancer: classification, histology and application of molecular pathology. J. Gastrointest. Oncol. 3, 251\u2013261. 10.3978/j.issn.2078-6891.2012.021", "ArticleIdList": ["10.3978/j.issn.2078-6891.2012.021", "PMC3418539", "22943016"]}, {"Citation": "Huang Y. Y., Yang Q., Zhou S. W., Wei Y., Chen Y. X., Xie D. R., et al. . (2013). Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis. PLoS ONE 8:e68939. 10.1371/journal.pone.0068939", "ArticleIdList": ["10.1371/journal.pone.0068939", "PMC3715514", "23874819"]}, {"Citation": "Jakesz R., Dittrich C., Funovics J., Hofbauer F., Rainer H., Reiner G., et al. . (1988). The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res. 110, 44\u201351. 10.1007/978-3-642-83293-2_6", "ArticleIdList": ["10.1007/978-3-642-83293-2_6", "3043596"]}, {"Citation": "Kim T. H., Park S. R., Ryu K. W., Kim Y. W., Bae J. M., Lee J. H., et al. . (2012). Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int. J. Radiat. Oncol. Biol. Phys. 84:e585\u2013592. 10.1016/j.ijrobp.2012.07.2378", "ArticleIdList": ["10.1016/j.ijrobp.2012.07.2378", "22975616"]}, {"Citation": "Krook J. E., O'Connell M. J., Wieand H. S., Beart R. W., Jr., Leigh J. E., Kugler J. W., et al. . (1991). A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67, 2454-2458.", "ArticleIdList": ["2015545"]}, {"Citation": "Kulig J., Kolodziejczyk P., Sierzega M., Bobrzynski L., Jedrys J., Popiela T., et al. . (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 78, 54\u201361. 10.1159/000292360", "ArticleIdList": ["10.1159/000292360", "20215786"]}, {"Citation": "Kwon H. C., Kim M. C., Kim K. H., Jang J. S., Oh S. Y., Kim S. H., et al. . (2010). Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac. J. Clin. Oncol. 6, 278\u2013285. 10.1111/j.1743-7563.2010.01331.x", "ArticleIdList": ["10.1111/j.1743-7563.2010.01331.x", "21114777"]}, {"Citation": "Li L. L., Xie C. Y., Su H. F. (2014). Benefit of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis. Tumour Biol. 35, 4957\u20134966. 10.1007/s13277-014-1653-2", "ArticleIdList": ["10.1007/s13277-014-1653-2", "24500665"]}, {"Citation": "Lim L., Michael M., Mann G. B., Leong T. (2005). Adjuvant therapy in gastric cancer. J. Clin. Oncol. 23, 6220\u20136232. 10.1200/JCO.2005.11.593", "ArticleIdList": ["10.1200/JCO.2005.11.593", "16135489"]}, {"Citation": "Lise M., Nitti D., Marchet A., Sahmoud T., Buyse M., Duez N., et al. . (1995). Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J. Clin. Oncol. 13, 2757\u20132763. 10.1200/JCO.1995.13.11.2757", "ArticleIdList": ["10.1200/JCO.1995.13.11.2757", "7595735"]}, {"Citation": "Macdonald J. S., Fleming T. R., Peterson R. F., Berenberg J. L., Mcclure S., Chapman R. A., et al. . (1995). Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a southwest oncology group study. Ann. Surg. Oncol. 2, 488\u2013494. 10.1007/BF02307081", "ArticleIdList": ["10.1007/BF02307081", "8591078"]}, {"Citation": "MacDonald J. S., Smalley S. R., Benedetti J., Hundahl S. A., Estes N. C., Stemmermann G. N., et al. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725\u2013730. 10.1056/NEJMoa010187", "ArticleIdList": ["10.1056/NEJMoa010187", "11547741"]}, {"Citation": "Min C., Bangalore S., Jhawar S., Guo Y., Nicholson J., Formenti S. C., et al. . (2014). Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology 86, 79\u201385. 10.1159/000354641", "ArticleIdList": ["10.1159/000354641", "24435019"]}, {"Citation": "Moertel C. G., Childs D. S., O'fallon J. R. (1984). Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J. Clin. Oncol. 2, 1249\u20131254. 10.1200/JCO.1984.2.11.1249", "ArticleIdList": ["10.1200/JCO.1984.2.11.1249", "6491703"]}, {"Citation": "Nakajima T., Nashimoto A., Kitamura M., Kito T., Iwanaga T., Okabayashi K., et al. . (1999). Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 354, 273\u2013277. 10.1016/S0140-6736(99)01048-X", "ArticleIdList": ["10.1016/S0140-6736(99)01048-X", "10440302"]}, {"Citation": "Nakajima T., Takahashi T., Takagi K., Kuno K., Kajitani T. (1984). Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 2, 1366\u20131371. 10.1200/JCO.1984.2.12.1366", "ArticleIdList": ["10.1200/JCO.1984.2.12.1366", "6439835"]}, {"Citation": "Nashimoto A., Nakajima T., Furukawa H., Kitamura M., Kinoshita T., Yamamura Y., et al. . (2003). Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan clinical oncology group 9206-1. J. Clin. Oncol. 21, 2282\u20132287. 10.1200/JCO.2003.06.103", "ArticleIdList": ["10.1200/JCO.2003.06.103", "12805327"]}, {"Citation": "Neri B., de Leonardis V., Romano S., Andreoli F., Pernice L. M., Bruno L., et al. . (1996). Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br. J. Cancer 73, 549\u2013552. 10.1038/bjc.1996.95", "ArticleIdList": ["10.1038/bjc.1996.95", "PMC2074461", "8595173"]}, {"Citation": "Nitti D., Wils J., Dos Santos J. G., Fountzilas G., Conte P. F., Sava C., et al. (2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann. Oncol. 17, 262\u2013269. 10.1093/annonc/mdj077", "ArticleIdList": ["10.1093/annonc/mdj077", "16293676"]}, {"Citation": "Norman G., Rice S., Spackman E., Stirk L., Danso-Appiah A., Suh D., et al. (2011). Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol. Assess. 15(Suppl. 1), 33\u201342. 10.3310/hta15suppl1/04", "ArticleIdList": ["10.3310/hta15suppl1/04", "21609651"]}, {"Citation": "Panzini I., Gianni L., Fattori P. P., Tassinari D., Imola M., Fabbri P., et al. . (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88, 21\u201327.", "ArticleIdList": ["12004845"]}, {"Citation": "Park S. H., Sohn T. S., Lee J., Lim D. H., Hong M. E., Kim K. M., et al. . (2015). Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J. Clin. Oncol. 33, 3130\u20133136. 10.1200/JCO.2014.58.3930", "ArticleIdList": ["10.1200/JCO.2014.58.3930", "25559811"]}, {"Citation": "Popiela T., Kulig J., Czupryna A., Szczepanik A. M., Zembala M. (2004). Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 7, 240\u2013245. 10.1007/s10120-004-0299-y", "ArticleIdList": ["10.1007/s10120-004-0299-y", "15616772"]}, {"Citation": "R\u00fccker G., Schwarzer G. (2015). Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med. Res. Methodol. 15:58 10.1186/s12874-015-0060-8", "ArticleIdList": ["10.1186/s12874-015-0060-8", "PMC4521472", "26227148"]}, {"Citation": "Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., et al. . (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810\u20131820. 10.1056/NEJMoa072252", "ArticleIdList": ["10.1056/NEJMoa072252", "17978289"]}, {"Citation": "Schlag P., Schreml W., Gaus W., Herfarth C., Linder M. M., Queisser W., et al. . (1982). Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res. 80, 277\u2013283. 10.1007/978-3-642-81685-7_44", "ArticleIdList": ["10.1007/978-3-642-81685-7_44", "7036292"]}, {"Citation": "Skoropad V., Berdov B., Zagrebin V. (2002). Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J. Surg. Oncol. 80, 72\u201378. 10.1002/jso.10102", "ArticleIdList": ["10.1002/jso.10102", "12173383"]}, {"Citation": "Smalley S. R., Benedetti J. K., Haller D. G., Hundahl S. A., Estes N. C., Ajani J. A., et al. . (2012). Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. 30, 2327\u20132333. 10.1200/JCO.2011.36.7136", "ArticleIdList": ["10.1200/JCO.2011.36.7136", "PMC4517071", "22585691"]}, {"Citation": "Song G. M., Liu X. L., Bian W., Wu J., Deng Y. H., Zhang H., et al. . (2017). Systematic review with network meta-analysis: comparative efficacy of different enteral immunonutrition formulas in patients underwent gastrectomy. Oncotarget 8, 23376\u201323388. 10.18632/oncotarget.15580", "ArticleIdList": ["10.18632/oncotarget.15580", "PMC5410311", "28423579"]}, {"Citation": "Soon Y. Y., Leong C. N., Tey J. C., Tham I. W., Lu J. J. (2014). Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis. J. Med. Imaging Radiat. Oncol. 58, 483\u2013496. 10.1111/1754-9485.12190", "ArticleIdList": ["10.1111/1754-9485.12190", "24995607"]}, {"Citation": "Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H. J., Riera-Knorrenschild J., et al. . (2009). Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol. 27, 851\u2013856. 10.1200/JCO.2008.17.0506", "ArticleIdList": ["10.1200/JCO.2008.17.0506", "19139439"]}, {"Citation": "Tsavaris N., Tentas K., Kosmidis P., Mylonakis N., Sakelaropoulos N., Kosmas C., et al. . (1996). A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 42, 220\u2013226. 10.1159/000239446", "ArticleIdList": ["10.1159/000239446", "8983891"]}, {"Citation": "Yu C., Yu R., Zhu W., Song Y., Li T. (2012). Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J. Cancer Res. Clin. Oncol. 138, 255\u2013259. 10.1007/s00432-011-1085-y", "ArticleIdList": ["10.1007/s00432-011-1085-y", "22105898"]}, {"Citation": "Zhou M. L., Kang M., Li G. C., Guo X. M., Zhang Z. (2016). Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J. Surg. Oncol. 14:209 10.1186/s12957-016-0957-7", "ArticleIdList": ["10.1186/s12957-016-0957-7", "PMC4977857", "27502921"]}, {"Citation": "Zhu L., Liu J., Ma S. (2016). Fluoropyrimidine-based chemotherapy as first-line treatment for advanced gastric cancer: a bayesian network meta-analysis. Pathol. Oncol. Res. 22, 853\u2013861. 10.1007/s12253-016-0078-1", "ArticleIdList": ["10.1007/s12253-016-0078-1", "27236591"]}, {"Citation": "Zhu W. G., Xua D. F., Pu J., Zong C. D., Li T., Tao G. Z., et al. . (2012). A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother. Oncol. 104, 361\u2013366. 10.1016/j.radonc.2012.08.024", "ArticleIdList": ["10.1016/j.radonc.2012.08.024", "22985776"]}, {"Citation": "Zhu X., Ko Y. J., Berry S., Shah K., Lee E., Chan K. (2016). A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer 20, 646\u2013654. 10.1007/s10120-016-0656-7", "ArticleIdList": ["10.1007/s10120-016-0656-7", "27722826"]}]}], "History": [{"Year": "2018", "Month": "6", "Day": "15"}, {"Year": "2018", "Month": "7", "Day": "30"}, {"Year": "2018", "Month": "9", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "9", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "9", "Day": "14", "Hour": "6", "Minute": "1"}, {"Year": "2018", "Month": "8", "Day": "22"}], "PublicationStatus": "epublish", "ArticleIdList": ["30210338", "PMC6119769", "10.3389/fphar.2018.00929"]}}]}